Expect heavy selling pressure as the market digests this massive dilutive offering. Monitor the stock for after-market trading; the offering effectively doubles the share count and signals significant cash burn. Avoid buying into weakness until the stock stabilizes post-offering.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $10.60entry
- T+1 · 6mo ago 0.00%α +0.14% · $10.60
- T+5 · 6mo ago −13.02%α −12.93% · $9.22
- T+20 · 5mo ago −31.42%α −31.11% · $7.27
- T+60 · 3mo ago +9.34%α +4.95% · $11.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics priced a $300M underwritten public offering of 23.9M shares and pre-funded warrants for 2.2M shares at $11.52 per share, equating to roughly 100% dilution of existing shares. The massive capital raise signals urgent cash needs for a pre-revenue biotech and will severely dilute existing shareholders.
Key Facts
- Offering of 23,871,526 shares and 2,170,138 pre-funded warrants for common stock
- Price: $11.52 per share; $11.5199 per pre-funded warrant
- Gross proceeds approximately $300 million
- Closing expected May 11, 2026
- Dilution of ~50% to ~100% relative to pre-offering share count
Financial Impact
Approximately $300 million gross proceeds, representing ~50-100% dilution of existing equity based on pre-offering market cap of ~$309 million
Risk Factors
- Extreme dilution to existing shareholders
- Potential for further capital raises if cash burn continues
- Downward pressure on stock price as new shares enter the market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-214711 |
| Document: d20969dex41.htm | 0001193125-26-214711 |
| Document: d20969d8k.htm | 0001193125-26-214711 |
| Document: d20969dex51.htm | 0001193125-26-214711 |
| Document: 0001193125-26-214711-index-headers.html | 0001193125-26-214711 |
| Document: 0001193125-26-214711-index.html | 0001193125-26-214711 |
| Document: 0001193125-26-214711.txt | 0001193125-26-214711 |
Track record
33 reports on ARTV
10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers